KEY PREDICTIVE FACTORS OF AXITINIB (AG-013736)-INDUCED PROTEINURIA AND EFFICACY: A JAPANESE PHASE II STUDY IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)

被引：0
|
作者：
Tomita, Y. [1 ]
Uemura, H. [2 ]
Fujimoto, H. [3 ]
Kanayama, H. [4 ]
Shinohara, N. [5 ]
Nakazawa, H. [6 ]
Ozono, S. [7 ]
Naito, S. [8 ]
Akaza, H. [9 ]
机构：
[1] Yamagata Univ, Sch Med, Yamagata 99023, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Univ Tokushima, Fac Med, Tokushima 770, Japan
[5] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[6] Tokyo Womens Med Univ, Med Ctr E, Tokyo, Japan
[7] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 4312102, Japan
[8] Kyushu Univ Hosp, Fukuoka 812, Japan
[9] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [41] Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study
    Rini, Brian I.
    Gruenwald, Viktor
    Fishman, Mayer N.
    Melichar, Bohuslav
    Ueda, Takeshi
    Karlov, Petr A.
    Bair, A. H.
    Chen, Ying
    Kim, Sinil
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).
    Powles, Thomas
    Wheater, Matthew James
    Din, Omar
    Geldart, Thomas R.
    Boleti, Ekaterini
    Stockdale, Andrew
    Sundar, Santhanam
    Robinson, Angus
    Ahmed, Imtiaz
    Sarker, Shah-Jalal
    Hussain, Syed A.
    Ralph, Christy
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [43] Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
    Choueiri, T. K.
    Kocsis, J.
    Pachynski, R. K.
    Poprach, A.
    Deshazo, M.
    Zakharia, Y.
    Lara, P. N.
    Pal, S. K.
    Geczi, L.
    Ho, T. H.
    Mangel, L.
    Redman, B.
    Ryan, C. W.
    Olencki, T.
    Simpson, B. E.
    Adams, B.
    Robertson, L.
    Darif, M.
    Theuer, C.
    Agarwal, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 362 - +
  • [44] Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
    Di Lorenzo, Giuseppe
    Carteni, Giacomo
    Autorino, Riccardo
    Bruni, Gianni
    Tudini, Marianna
    Rizzo, Mimma
    Aieta, Michele
    Gonnella, Antonio
    Rescigno, Pasquale
    Perdona, Sisto
    Giannarini, Gianluca
    Pignata, Sandro
    Longo, Nicola
    Palmieri, Giovannella
    Imbimbo, Ciro
    De Laurentiis, Michele
    Mirone, Vincenzo
    Ficorella, Corrado
    De Placido, Sabino
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4469 - 4474
  • [45] A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC)
    Rugo, H. S.
    Stopeck, A.
    Joy, A. A.
    Chan, S.
    Verma, S.
    Lluch, A.
    Liau, K. F.
    Kim, S.
    Bycott, P.
    Soulieres, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
    Iacovelli, R.
    Ciccarese, C.
    Bersanelli, M.
    Zucali, P. A.
    Fantinel, E.
    Bimbatti, D.
    Verzoni, E.
    Accettura, C.
    Bonomi, L.
    Buttigliero, C.
    Fornarini, G.
    Pipitone, S.
    Atzori, F.
    Masini, C.
    Massari, F.
    Primi, F.
    Buti, S.
    Perrino, M. R. A.
    Pafumi, S.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1013 - S1013
  • [47] A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety
    Uemura, Hirotsugu
    Shinohara, Nobuo
    Yuasa, Takeshi
    Tomita, Yoshihiko
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Mugiya, Soichi
    Miki, Tsuneharu
    Nonomura, Norio
    Takahashi, Masayuki
    Hasegawa, Yoshihiro
    Agata, Naoki
    Houk, Brett
    Naito, Seiji
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (03) : 194 - 202
  • [48] FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY
    Stewart, Grant
    Morden, James
    Boleti, Ekaterini
    Vasudev, Naveen
    Thistlethwaite, Fiona
    Michael, Agnieszka
    Kilburn, Lucy
    Lewis, Rebecca
    Nicol, David
    Pyle, Linda
    Snowdon, Claire
    Todd, Rachel
    Tregellas, Lucy
    Turajlic, Samra
    Swanton, Charlie
    Bliss, Judith
    Larkin, James
    JOURNAL OF UROLOGY, 2017, 197 (04): : E917 - E917
  • [49] A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy (CRUKE/11/061)
    Fisher, Rosalie A.
    Rowan, Andrew
    Stares, Mark
    Webster-Smith, Mark F.
    Lewis, Rebecca
    Kilbum, Lucy S.
    Nicol, David
    Stewart, Grant
    Michael, Agnleszka
    Vasudev, Naveen
    Hazen, Steve
    Turalijic, Samra
    Pickering, Lisa M.
    Gore, Martin Eric
    Snowdon, Claire
    Bliss, Judith M.
    Swanton, Charles
    Larkin, James M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results
    Tomasello, L.
    Sertoli, M. R.
    Rubagotti, A.
    Guglielmini, P.
    Tacchini, L.
    Bedognetti, D.
    Ricci, F.
    Sanguineti, S.
    Cassata, A.
    Boccardo, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345